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ABSTRACT
Objective: The objective was to evaluate the efficacy of ormeloxifene in dysfunctional uterine bleeding (DUB) with respect to bleeding pattern and 
improvement in hemoglobin (Hb).
Methods: This was an interventional study on 99 patients of DUB visiting the gynecology outpatient department over 1 year using semi-structured 
pro forma. After voluntary participation of patients, tablet ormeloxifene was given at the dose of 30 mg biweekly for 2 months. In case of a therapeutic 
response as informed by the patient, the dose was reduced to 30 mg weekly for a further period of 4 months. All patients were treated for 6 months. 
Type, amount, and duration of bleeding, frequency of menstrual cycle, passage of clots, and impact on Hb were assessed.
Result and Observations: Menorrhagia was the main type of bleeding. 36–40 years of age group was the most common. After the intervention, 76.8% 
of women achieved a duration of bleeding of 4–5 days, and in 87% of women, menstrual cycle became regular. Passage of clots was reduced by 71.83%. 
Mean Hb concentration of study participants increased by 0.5 g/dl at the end of the study.
Conclusion: Ormeloxifene is effective alternative and appears to be a promising option for the medical management of DUB.
Keywords: Dysfunctional uterine bleeding, Ormeloxifene, Hemoglobin, Menorrhagia, Selective estrogen receptor modulators.
INTRODUCTION
Dysfunctional uterine bleeding (DUB) is abnormal genital tract 
bleeding based in the uterus and found in the absence of demonstrable 
structural or organic pathology [1,2].
Such bleeding is often the result of endocrinological dysfunction and 
is associated with the absence of ovulation in 80–85% of cases [3,4]. 
DUB is a common debilitating problem among women in all age groups 
and accounts for 20% of gynecology clinic visits [5]. Even though a 
number of treatment modalities are available, a reliable drug for the 
management of DUB should meet the requirements such as drug should 
be effective, convenient to take, cost of the drug must be low, with 
minimal side effects, and the drug should have longest safety margin. 
The latest of the pharmacological agents that have become available 
for the treatment of DUB are selective estrogen receptor modulators. 
These are designer drugs which have an affinity to the estrogen 
receptor and act like estrogens in some tissues and have antiestrogenic 
effects in others [6]. Ormeloxifene is a non-steroidal selective estrogen 
receptor modifier with strong antiestrogen and weak estrogenic and 
antiprogestin properties [7]. Ormeloxifene not only preferred as oral 
contraceptive but also useful for the management of DUB and advanced 
breast cancer [8-10].
METHODS
This was an interventional study of 99 patients, carried out in 
gynecological outpatient department of medical college and hospital at 
Dhule district. It was 1 year study and comprised of semi-structured 
type pro forma including information related to the physical status of 
participants. Patients’ weight was noted, and menstrual history was 
taken in detail. Patients who were between 20 and 40 years of age, who 
are not desirous of pregnancy, and who were with no organic disease 
were included. A total of 106 patients registered in the OPD of the 
gynecology department were the study population.
Emphasis was paid on the type of bleeding, duration of bleeding, type of 
blood loss, duration of cycles, passage of clots, and effect on hemoglobin 
concentration. Treatment taken for present complaints was enquired 
and previous menstrual history was also noted. History suggestive of 
bleeding disorders, diabetes, and thyroid dysfunction was also taken. 
Obstetric and family history was noted.
Of  these patients, 99 patients who were fulfilling inclusion criteria’s and who 
were ready to participate in the study voluntarily were enrolled. Voluntarily 
participated patients were given tablet ormeloxifeneat the dose of 30 mg 
biweekly for 2 months. The patient was reassessed after the first 2 months. 
Blood loss was assessed in a subjective manner and by hemoglobin 
estimation. In case of a therapeutic response as informed by the patient, 
the dose was reduced to 30 mg weekly for a further period of 4 months. All 
patients were treated for 6 months. Patients were analyzed after 6 months, 
and data collected were tabulated and analyzed using computer technology 
by the SPSS package of statistics. Protocol was submitted to the Institutional 
Ethics Committee, and the study was started after approval.
RESULTS AND OBSERVATIONS
Of 99 patients, nearly 50.51% of women were in 36–40 years of age 
group. Maximum number of women, i.e., 52.53% were of third parity. 
Menorrhagia was the main type of bleeding (58.2%) (Table 1).
In age-wise distribution, 53.40% of women who were having 
menorrhagia were in 36–40 years of age group (Table 2).
Duration of bleeding was 4–5 days in 12.1%, but after ormeloxifene, it 
changed to 76.8% (p=0.001) (Table 3).
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After intervention for 6 months, the frequency of menstrual cycle which 
was irregular in 74.7% changed to regular (12.1%), and regular cycle 
pattern (25.3%) increased to 87.9% (Table 4).
Amount of bleeding returns to normal in 68.7% and heavy blood loss 
turned to 0% from 85.9% (Table 5).
Women showing the history of passage of clots were significantly 
decreased from 78.9% to 7.07%.
At the time of participation in the study, it was observed that all women 
were having hemoglobin below 12 g/dl. The cumulative percentage of 
70.7% of women was having hemoglobin <10 g/dl, of which 32.3% of 
women had hemoglobin concentration between 9 and 10 g/dl. After the 
intervention, the cumulative percentage of women having hemoglobin 
<10 g/dl reduced to 61.6%, of which most of them, i.e., 36.4% were having 
hemoglobin (Hb) from 9 to 10gm/dl. Furthermore, there was a significant 
improvement in Hb concentration in women having Hb in between 10 and 
12 g/dl from 29.3% to 38.4% after intervention. Mean Hb concentration of 
study participants increased from 9.5 g/dl to 10 g dl at the end of the study.
DISCUSSION
Wide varieties of treatment modalities are available for treating DUB, 
from medical therapy to minimally invasive surgery in the form of 
transcervical resection of the endometrium, thermal ablation, and 
others to conventional hysterectomy. However, medical treatment 
should be the preferred modality of treatment when possible [11]. 
A medical management is the first line of therapy for dysfunctional 
uterine bleeding. The agents that have been used to treat menorrhagia 
include iron, cyclooxygenase inhibitors, desmopressin, antifibrinolytics, 
gonadotropin-releasing hormone agonists, androgens, combined oral 
contraceptives, and progestins [12]. Ormeloxifene has been found to be 
safer and effective alternative in the treatment of DUB.
The most common age presentation in our study was between 31 and 
40 years. It was believed earlier that DUB is more common in extremes 
of reproductive ages, but the current scenario does not show strictness 
in above fact [2]. Study by Agarwal and SIngh selected age range of 20- 50 
years [13]. In clinical practice, age can vary from 30 to 45 years. DUB 
was seen commonly in multiparous than nullipara or primipara women. 
Annigeri et al. and Mandal et al. found that 85.33% of multiparous 
women were having DUB [2,11]. In some studies like Grover et al., only 
multiparous women were selected as participants [14].
Among bleeding pattern, menorrhagia was the most common (58.2%). 
In a study conducted by Annigeri et al. and Komaram et al., the common 
pattern was menorrhagia and was found in 73.16% and 44% of women, 
respectively [2,15].
45.5% of women were having >8 days of bleeding before intervention 
which reduced to 2% after intervention. Ormeloxifene has a significant 
effect on bleeding duration. The same results were seen with Shabab 
et al., Godha et al. [12,16] (mean duration of bleeding reduced to 4.8 
from 9), Grover et al. [14] (total bleeding days decreased by 76% 
with treatment), Soniya et al. [17] (81.63% of patients got relief from 
Table 4: Effect of 6 months ormeloxifene on the frequency of 
menstrual cycle






Irregular 74 (74.7) 12 (12.1)
Regular 25 (25.3) 87 (87.9)
Chi-square (McNemar) p=0.001
Table 5: Effect of 6 months of ormeloxifene on amount of 
bleeding
Amount of  
bleeding
Pretreatment n (%) After treatment n (%)
Normal 0 (0) 68 (68.7)
Moderate 14 (14.1) 31 (31.3)
Heavy 85 (85.9) 0 (0)
Wilcoxon sign rank test p=0.001
Table 6: Comparison among related studies
Studies Improvement in 
mean Hb (g/dl)
% reduction in  
passage of clots
Current study 0.5 71.83
Grover et al. [14] 0.42 66.66
Mandal et al. [11] 0.72 80.6
Bhattacharyya and Banerji [19] 2.53 91.18
Singh et al. [18] 1.89 51.7
Jacob et al. [20] 1.39 93.3
Agarwal and Singh [13] 0.7 67
Ahmed et al. [21] 1.96 68
Godha et al. [16] 1.2 87
Komaram et al. [15] 1.3 59
Dhananjay et al. [22] 2.26 -
Khan et al. [23] 1.3 -
Table 1: Age, parity, and bleeding pattern‑wise distribution of 
patients












3 Type of bleeding
Menorrhagia 58 (58.2)
Metropathia hemorrhagica 10 (10)
Polymenorrhagia 23 (24)
Metrorrhagia 8 (7.8)
Table 2: Age group wise distribution of type of bleeding
Parameters Age in years (%) Total
20–25 26–30 31–35 36–40
Menorrhagia 5 (8.6) 8 (13.8) 14 (24.1) 31 (53.4) 58 (100)
Polymenorrhagia 4 (17.4) 2 (8.7) 7 (30.4) 10 (43.5) 23 (100)
Metropathia 
hemorrhagica
0 (0) 2 (20) 3 (30) 5 (50) 10 (100)
Metrorrhagia 0 (0) 2 (25) 2 (25) 4 (50) 8 (100)
Total 9 (9.1) 1 (14.1) 26 (26.3) 50 (50.5) 99 (100)
Table 3: Effect of ormeloxifene treatment for 6 months on the 
duration of menstrual bleeding







<4 days 0 (0) 21 (21.2) 0.001
4–5 days 12 (12.1) 76 (76.8) 0.001
6–7 days 42 (42.4) 0 (0) 0.001
≥8 days 45 (45.5) 2 (2) 0.001
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menorrhagia), and Mandal et al. [11] (reduction in menstrual blood 
flow in 61.11%). Reduction in total bleeding days was indirectly 
reflected an increase in Hb level.
The regular menstrual pattern was achieved in 87.9% of women. In 
a study conducted by Grover et al., 66.7% of women achieved regular 
menses at the end of 3 months’ treatment [14]. This number may go up 
after 6 months of treatment.
In our study, 85.9% of women were having heavy bleeding which reduced 
to zero at the end of treatment. This finding is in line with a study by Singh 
et al., in which 53.32% pretreatment value reduced to 4.65% [18].
Passages of clots were significantly reduced to 7.07% from 78.9%. There 
are many studies which show the result in line with our study. There 
was a significant improvement in Hb concentration. Mean Hb improved 
from 9.5 to 10 g/dl. There are several studies which showed near similar 
results  (Table 6).
CONCLUSION
Ormeloxifene is an effective alternative and appears to be a promising 
option for the medical management of DUB. It has a convenient dosing 
schedule. Ormeloxifene reduced the duration of bleeding significantly, 
and menstrual cycle became regular. It showed a positive impact on 
the amount of bleeding. Passages of clots were reduced and mean 
hemoglobin was increased. Along with being effective, the drug has a 
good patient acceptability and compliance and simple dosage schedule.
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